胆汁淤积性瘙痒发病机制及其治疗研究进展
收稿日期: 2021-11-21
网络出版日期: 2022-07-25
基金资助
上海市科学技术委员会科技计划项目(20ZR1450100);上海市浦东新区临床特色学科基金项目(PWYts 2021-11)
鲁晓岚, 夏巧云 . 胆汁淤积性瘙痒发病机制及其治疗研究进展[J]. 内科理论与实践, 2022 , 17(01) : 43 -47 . DOI: 10.16138/j.1673-6087.2022.01.008
| [1] | Trivella J, Levy C. Safety considerations for the management of cholestatic itch[J]. Expert Opin Drug Saf, 2021, 20(8): 915-924. |
| [2] | Lieu T, Jayaweera G, Zhao P, et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice[J]. Gastroenterology, 2014, 147(6): 1417-1428. |
| [3] | Yu H, Zhao T, Liu S, et al. MRGPRX4 is a bile acid receptor for human cholestatic itch[J]. Elife, 2019, 8: e48431. |
| [4] | Cipriani S, Renga B, D’Amore C, et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling[J]. PLoS One, 2015, 10(7): e0129866. |
| [5] | Yu H, Wangensteen K, Deng T, et al. MRGPRX4 in cholestatic pruritus[J]. Semin Liver Dis, 2021, 41(3): 358-367. |
| [6] | Meixiong J, Vasavda C, Green D, et al. Identification of a bilirubin receptor that may mediate a component of cholestatic itch[J]. Elife, 2019, 8: e44116. |
| [7] | Patel SP, Vasavda C, Ho B, et al. Cholestatic pruritus: emerging mechanisms and therapeutics[J]. J Am Acad Dermatol, 2019, 81(6): 1371-1378. |
| [8] | Kittaka H, Uchida K, Fukuta N, et al. Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1/TRPV1[J]. J Physiol, 2017, 595(8): 2681-2698. |
| [9] | Tian B, Wang XL, Huang Y, et al. Peripheral and spinal 5-HT receptors participate in cholestatic itch and antinociception induced by bile duct ligation in rats[J]. Sci Rep, 2016, 6: 36286. |
| [10] | Ostadhadi S, Kordjazy N, Haj-Mirzaian A, et al. 5-HT3 receptors antagonists reduce serotonin-induced scratching in mice[J]. Fundam Clin Pharmacol, 2015, 29(3): 310-315. |
| [11] | Shimizu K, Andoh T, Yoshihisa Y, et al. Histamine released from epidermal keratinocytes plays a role in α-melanocyte-stimulating hormone-induced itching in mice[J]. Am J Pathol, 2015, 185(11): 3003-3010. |
| [12] | Andoh T, Suzuki K, Konno M, et al. Pharmacological characterization of a novel mouse model of cholestatic pruritus[J]. Biol Pharm Bull, 2020, 43(7): 1111-1117. |
| [13] | Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists: Relevant after all these years[J]. Med Hypotheses, 2018, 110: 86-89. |
| [14] | Moniaga CS, Iwamoto S, Kitamura T, et al. Plasma dynorphin a concentration reflects the degree of pruritus in chronic liver disease[J]. Acta Derm Venereol, 2019, 99(4): 442-443. |
| [15] | Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial[J]. Hepatol Res, 2017, 47(10): 972-982. |
| [16] | Düll MM, Wolf K, Vetter M, et al. Endogenous opioid levels do not correlate with itch intensity and therapeutic interventions in hepatic pruritus[J]. Front Med (Lausanne), 2021, 8: 641163. |
| [17] | Wang Q, Hao C, Yao W, et al. Intestinal flora imbalance affects bile acid metabolism and is associated with gallstone formation[J]. BMC Gastroenterol, 2020, 20(1): 59. |
| [18] | Kitahata S, Yamamoto Y, Yoshida O, et al. Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis[J]. Sci Rep, 2021, 11(1): 19705. |
| [19] | Rossen NG, Fuentes S, Boonstra K, et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured clostridiales Ⅱ[J]. J Crohns Colitis, 2015, 9(4): 342-348. |
| [20] | Zhan Q, Qi X, Weng R, et al. Alterations of the human gut microbiota in intrahepatic cholestasis of pregnancy[J]. Front Cell Infect Microbiol, 2021, 11: 635680. |
| [21] | Ji SG, Juran BD, Mucha S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease[J]. Nat Genet, 2017, 49(2): 269-273. |
| [22] | Kim MJ, Kim JY, Kang M, et al. Reduced fecal calprotectin and inflammation in a murine model of atopic dermatitis following probiotic treatment[J]. Int J Mol Sci, 2020, 21(11): 3968. |
| [23] | Kim IS, Lee SH, Kwon YM, et al. Oral administration of β-glucan and lactobacillus plantarum alleviates atopic dermatitis-like symptoms[J]. J Microbiol Biotechnol, 2019, 29(11): 1693-1706. |
| [24] | Sanjel B, Shim WS. Recent advances in understanding the molecular mechanisms of cholestatic pruritus[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(12): 165958. |
| [25] | De Vloo C, Nevens F. Cholestatic pruritus: an update[J]. Acta Gastroenterol Belg, 2019, 82(1): 75-82. |
| [26] | Ahmadi AR, Chicco M, van den Berge M. Rifampicin for treatment of cholestatic pruritus caused by drug-induced acute liver injury as assessed by the RUCAM classification[J]. Case Reports Hepatol, 2020, 2020: 8872804. |
| [27] | Webb GJ, Rahman SR, Levy C, et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study[J]. Aliment Pharmacol Ther, 2018, 47(8): 1213-1219. |
| [28] | Murray-Brown FL. Naltrexone for cholestatic itch: a systematic review[J]. BMJ Support Palliat Care, 2021, 11(2): 217-225. |
| [29] | European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. |
| [30] | Thébaut A, Habes D, Gottrand F, et al. Sertraline as an additional treatment for cholestatic pruritus in children[J]. J Pediatr Gastroenterol Nutr, 2017, 64(3): 431-435. |
| [31] | Ovadia C, Lövgren-Sandblom A, Edwards LA, et al. Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: case series and mechanism of action[J]. J Clin Apher, 2018, 33(6): 638-644. |
| [32] | Chkheidze R, Joseph R, Burner J, et al. Plasma exchange for the management of refractory pruritus of cholestasis: a report of three cases and review of literature[J]. J Clin Apher, 2018, 33(3): 412-418. |
| [33] | Pantzaris ND, Lord T, Sotheran R, et al. Nasobiliary drain diverted through a percutaneous endoscopic gastrostomy tube[J]. Case Rep Gastroenterol, 2021, 15(3): 891-897. |
| [34] | Hussain AB, Samuel R, Hegade VS, et al. Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy[J]. Br J Dermatol, 2019, 181(6): 1138-1145. |
| [35] | Ziogas IA, Alexopoulos SP, Matsuoka LK, et al. Living vs deceased donor liver transplantation in cholestatic liver disease: an analysis of the OPTN database[J]. Clin Transplant, 2020, 34(10): e14031. |
| [36] | Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study[J]. Lancet, 2017, 389(10074): 1114-1123. |
| [37] | Al-Dury S, Wahlström A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis[J]. Sci Rep, 2018, 8(1): 6658. |
/
| 〈 |
|
〉 |
